Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.

作者: David J. Schneider

DOI: 10.1111/J.1365-2125.2010.03879.X

关键词: Platelet activationGlycoprotein IIb/IIIaClinical trialPlatelet aggregation inhibitorHeparinPharmacologyMedicineConventional PCIPlateletPlatelet Glycoprotein GPIIb-IIIa Complex

摘要: Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. Three agents are approved for clinical use. In this review, characteristics each agent, their pharmacodynamic profile, results in pivotal trials and associated implications discussed. GP have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) patient has intra-coronary thrombosis. These appear to provide combination with heparin. The niche parenteral is evolving. rapid onset offset plus dosing designed extensively platelet differentiates them from oral agents. contemporary appears include patients transition, such individuals requiring emergent PCI before fully active unstable transport centres, particularly likely intracoronary thrombus. Subsequent studies should evaluate optimal duration antagonists.

参考文章(85)
J.W. Weisel, C Nagaswami, G Vilaire, J.S. Bennett, Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. Journal of Biological Chemistry. ,vol. 267, pp. 16637- 16643 ,(1992) , 10.1016/S0021-9258(18)42050-9
Eric J. Topol, J.Donald Easton, Pierre Amarenco, Robert Califf, Robert Harrington, Carmen Graffagnino, Stephen Davis, H.C. Diener, James Ferguson, Desmond Fitzgerald, Ashfaq Shuaib, Peter J. Koudstaal, Pierre Theroux, Frans Van de Werf, James T. Willerson, Robert Chan, Robert Samuels, Bernard Ilson, Jeffrey Granett, Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. American Heart Journal. ,vol. 139, pp. 927- 933 ,(2000) , 10.1067/MHJ.2000.105107
Dean J. Kereiakes MD, Todd Lorenz MD, John J. Young MD, Gilbert Kukielka MD, Michele N. Mueller PBT(ASCP), Lisa Nanniazzi-Alaimo BSc, David R. Phillips MD, Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban Journal of Thrombosis and Thrombolysis. ,vol. 12, pp. 123- 127 ,(2001) , 10.1023/A:1012991303381